To examine the clinical significance of MALAT1-associated DDR genes, we performed Kaplan–Meier survival analysis for recurrence-free survival using the RNA-seq data of patients with prostate cancer from the TCGA-PRAD cohort categorized into two groups based on the median expression of MALAT1 and selected DDR genes. This evidence concerns the gene MALAT1 and prostate adenocarcinoma.